1 near-penny stock I’m buying for the last time at 19p

Our writer explains why a penny stock he bought a couple of years ago has taken a big dip since Donald Trump was elected in November.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

British Pennies on a Pound Note

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

hVIVO (LSE: HVO) was a penny stock when I first bought it at 11p in late 2022. By July 2024, it spiked at 30p and I was sitting pretty (or so I thought).

The market cap had also surpassed £200m by then, disqualifying it from being called a penny stock. In the UK, those are often seen as stocks with a market cap under £100m as well as a share price beneath 100p.

Now, as I write (26 December), the share price has pulled back sharply to 19.56p. I’m still up, but I also bought shares in the summer at 29p and that purchase is down sharply too.

Should you invest £1,000 in Aviva right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Aviva made the list?

See the 6 stocks

To be fair, I knew what I was getting myself into, as small-caps and penny stocks are prone to stomach-churning bouts of volatility. This one’s certainly been no exception to the rule.

Yet I’m ready to take one last nibble on hVIVO shares in early January. Here’s why.

Created with Highcharts 11.4.3hVIVO Plc PriceZoom1M3M6MYTD1Y5Y10YALL28 Dec 201928 Dec 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

What is hVIVO?

For those unfamiliar, hVIVO is a firm that specialises in human challenge trials (HCTs), a growing niche market within the massive contract research organisation industry.

HCTs involve deliberately infecting healthy volunteers with a pathogen in a controlled environment to test treatments. The firm recruits these paid volunteers — many of them students in need of some cash — through its own FluCamp business.

hVIVO works with four of the top 10 global pharmaceutical companies. It conducted the world’s first Covid HCT during the pandemic, generating data that advanced understanding of the virus and helped guide vaccine development.

However, ‘vaccine’ has become a bit of a dirty word in some quarters following the US election.

Dark clouds

In November, Donald Trump nominated vaccine-sceptic Robert Kennedy Jr to lead the Department of Health and Human Services. We don’t know whether he’ll get the gig, but the market isn’t waiting to find out. The hVIVO share price is down 30% since then.

The fear seems to be that if major pharmaceutical companies anticipate a hostile regulatory or funding environment under Kennedy, they might reduce investments in vaccine-related projects. This could affect hVIVO’s pipeline of contracts and growth trajectory.

But the future still looks sunny

The truth is we don’t yet know how things will play out. What we do know however is that the company recently signed an £11.5m contract with an unnamed blue-chip pharmaceutical client to test a new antiviral candidate for respiratory syncytial virus (RSV).

This virus affects around 33m people annually, leading to approximately 4m hospitalisations worldwide and 101,000 deaths in children under five years old.

CEO Yamin ‘Mo’ Khan commented: “This contract further demonstrates the trust and confidence that leading pharmaceutical companies place in hVIVO’s human challenge study models.”

The study is scheduled to commence in H2 2025, with revenue recognised across 2025 and 2026. For 2024, management expects revenue of £62m, with a healthy EBITDA margin of around 22%-24%. And it’s targeting £100m in revenue by 2028.

hVIVO is an industry leader in human challenge trials, a market which is expected to grow from $100m-$150m today to as much as $1bn in the years ahead.

The business is highly cash generative and debt free. It’s even started paying a small dividend.

Lastly, with the stock on a forward price-to-earnings multiple of 11.7, the valuation looks very attractive.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Aviva right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Aviva made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in hVIVO Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Stack of British pound coins falling on list of share prices
Investing Articles

Why hasn’t its 9.9% yield boosted the Phoenix share price?

Phoenix Group has a dividend close to double digits, but saw a weak share price performance in recent years. Christopher…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

With average 10% yields, these mid-cap FTSE shares could supercharge a passive income portfolio

Some of the best passive income gems can be found on the UK's smaller indexes like the FTSE 250 and…

Read more »

A coin being dropped into a piggy bank
Investing Articles

As the Barclays share price tanks 19% in 2 days, is this a great buying opportunity?

As a trade war sends the Barclays share price into a tailspin, Andrew Mackie steps back to look at the…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is Fundsmith Equity still a good choice for a Stocks and Shares ISA in 2025?

Many Britons hold the Fundsmith Equity fund in their Stocks and Shares ISAs. Is this still a good move? Edward…

Read more »

Investing Articles

Nvidia stock is down 24% this year. Time to buy the dip?

Christopher Ruane has been eyeing Nvidia stock as a potential addition to his portfolio for a while. Is a recent…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Down 25% since January, this resilient dividend stock’s catching my eye

Maintaining the UK’s rail, water, and energy infrastructure isn’t the most exciting business. But it has made this a solid…

Read more »

Investing Articles

Prediction: Unilever to outperform the FTSE 100 over the next 12 months

The FTSE 100 has made a strong start to 2025, but Stephen Wright thinks a popular dividend stock could be…

Read more »

Investing Articles

I just bought this legendary S&P 500 tech stock for my ISA, 27% off its highs

This S&P 500 stock has tanked over the last month and Edward Sheldon has snapped it up for his portfolio…

Read more »